T-cell costimulation--biology, therapeutic potential, and challenges.

PubWeight™: 2.81‹?› | Rank: Top 1%

🔗 View Article (PMID 16908487)

Published in N Engl J Med on August 14, 2006

Authors

Arlene H Sharpe1, Abul K Abbas

Author Affiliations

1: Harvard Medical School, Boston, USA.

Articles citing this

Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol (2009) 2.48

The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23

BCL11B is required for positive selection and survival of double-positive thymocytes. J Exp Med (2007) 1.59

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol (2007) 1.44

T-cell costimulation and coinhibition in atherosclerosis. Circ Res (2008) 1.32

CD28 co-stimulation down regulates Th17 development. PLoS One (2009) 1.28

Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS One (2008) 1.09

Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation. J Immunol (2010) 1.04

New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol (2013) 1.01

Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun (2008) 0.99

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98

The problems and promises of research into human immunology and autoimmune disease. Nat Med (2012) 0.94

Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology (2015) 0.92

Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells. Front Oncol (2012) 0.89

Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity (2016) 0.88

Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer. Biomed Res Int (2013) 0.87

Dynamics of a cytokine storm. PLoS One (2012) 0.85

Antigenic experience dictates functional role of glycogen synthase kinase-3 in human CD4+ T cell responses. J Immunol (2008) 0.85

Allogeneic murine mesenchymal stem cells: migration to inflamed joints in vivo and amelioration of collagen induced arthritis when transduced to express CTLA4Ig. Stem Cells Dev (2013) 0.82

Diffusive transfer between two intensely interacting cells with limited surface kinetics. Chem Eng Sci (2012) 0.82

The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium. Inflammation (2012) 0.82

Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection. Biologics (2012) 0.81

Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid (2012) 0.81

Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications. Clin Dev Immunol (2012) 0.80

Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol (2015) 0.79

CD8⁺ T-cell counts: an early predictor of risk and mortality in critically ill immunocompromised patients with invasive pulmonary aspergillosis. Crit Care (2013) 0.79

Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens. J Virol (2014) 0.78

Volunteers at risk. N Engl J Med (2006) 0.77

Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) (2013) 0.76

T-cell costimulation. N Engl J Med (2006) 0.75

Dysregulating the regulators. J Biol (2009) 0.75

T-cell costimulation. N Engl J Med (2006) 0.75

The expression and distribution of immunomodulatory proteins B7-H1, B7-DC, B7-H3, and B7-H4 in rheumatoid synovium. Clin Rheumatol (2011) 0.75

Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol (2013) 0.75

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Oncologist (2016) 0.75

Articles cited by this

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04

Articles by these authors

Natural versus adaptive regulatory T cells. Nat Rev Immunol (2003) 8.74

Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med (2003) 5.23

Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med (2002) 3.80

Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70

The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol (2002) 3.47

Response to self antigen imprints regulatory memory in tissues. Nature (2011) 2.96

Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med (2006) 2.46

Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13

Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med (2007) 1.99

Memory regulatory T cells reside in human skin. J Clin Invest (2014) 1.95

Regulatory T cells in the periphery. Immunol Rev (2006) 1.94

The initial phase of an immune response functions to activate regulatory T cells. J Immunol (2009) 1.88

Interleukin-2 in the development and control of inflammatory disease. Immunol Rev (2008) 1.83

Paths to understanding the genetic basis of autoimmune disease. Nature (2005) 1.79

Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol (2010) 1.79

A resource for the conditional ablation of microRNAs in the mouse. Cell Rep (2012) 1.66

Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol (2009) 1.66

CD4+CD25+ cells controlling a pathogenic CD4 response inhibit cytokine differentiation, CXCR-3 expression, and tissue invasion. J Immunol (2004) 1.66

The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol (2003) 1.57

IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54

Cutting edge: the Th1 response inhibits the generation of peripheral regulatory T cells. J Immunol (2009) 1.52

STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms. J Immunol (2010) 1.33

Cutting Edge: memory regulatory t cells require IL-7 and not IL-2 for their maintenance in peripheral tissues. J Immunol (2013) 1.29

Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen. J Exp Med (2004) 1.23

Role of B7 in T cell tolerance. J Immunol (2004) 1.21

IL-2 induces a competitive survival advantage in T lymphocytes. J Immunol (2004) 1.20

CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen. J Immunol (2002) 1.19

Functional and molecular comparison of anergic and regulatory T lymphocytes. J Immunol (2006) 1.17

Treating human autoimmunity: current practice and future prospects. Sci Transl Med (2012) 1.16

Control of CD4+ T-cell memory by cytokines and costimulators. Immunol Rev (2006) 1.14

The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance. J Immunol (2005) 1.12

Distinct regions in the CD28 cytoplasmic domain are required for T helper type 2 differentiation. Nat Immunol (2004) 1.08

Posttranscriptional silencing of effector cytokine mRNA underlies the anergic phenotype of self-reactive T cells. Immunity (2011) 1.07

CD28 signals in the immature immunological synapse. J Immunol (2004) 1.06

T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunol Rev (2005) 1.06

Duration of antigen receptor signaling determines T-cell tolerance or activation. Proc Natl Acad Sci U S A (2010) 1.05

B7-independent inhibition of T cells by CTLA-4. J Immunol (2005) 1.05

Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest (2006) 1.05

Distinct roles of helper T-cell subsets in a systemic autoimmune disease. Blood (2008) 1.04

Cutting edge: contributions of apoptosis and anergy to systemic T cell tolerance. J Immunol (2008) 0.94

Targeting T cell-specific costimulators and growth factors in a model of autoimmune hemolytic anemia. J Immunol (2007) 0.94

Cutting edge: Self-antigen controls the balance between effector and regulatory T cells in peripheral tissues. J Immunol (2014) 0.92

Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol (2007) 0.91

Role of T cells in a murine model of Escherichia coli sepsis. Eur J Immunol (2007) 0.91

The life of regulatory T cells. Ann N Y Acad Sci (2013) 0.88

Mechanisms of human autoimmunity. J Clin Invest (2015) 0.87

Revisiting the role of IL-2 in autoimmunity. Eur J Immunol (2010) 0.87

Balance of Th1 and Th17 effector and peripheral regulatory T cells. Microbes Infect (2009) 0.87

Opposing functions of IL-2 and IL-7 in the regulation of immune responses. Cytokine (2011) 0.82

Life and death in effector T cells. Nat Immunol (2002) 0.82

Differential requirements for Th1 and Th17 responses to a systemic self-antigen. J Immunol (2011) 0.81

Dendritic cells giveth and taketh away. Nat Immunol (2005) 0.77

Retraction. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity (2009) 0.77

Functional tolerance is maintained despite proliferation of CD4 T cells after encounter with tissue-derived antigen. Dev Immunol (2002) 0.75

A network of regulatory pathways in lepromatous leprosy. Clin Immunol (2011) 0.75

Retraction. Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes. Immunity (2009) 0.75

Pillars article: antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. 1984. J Immunol (2007) 0.75

Retraction. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity (2009) 0.75